BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36430262)

  • 1. TFG-β Nuclear Staining as a Potential Relapse Risk Factor in Early-Stage Non-Small-Cell Lung Cancer.
    Cárdenas-Quesada N; Díaz-Beltrán L; Rosa-Garrido C; Márquez-Lobo B; Sabio-González A; Luque-Barona RJ; Núñez MI; Sánchez-Rovira P
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
    Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH
    Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of PD-L1 expression in combination with CD8
    Yang H; Shi J; Lin D; Li X; Zhao C; Wang Q; Zhang L; Jiang T; Zhao S; Liu X; Jia Y; Zhang Y; Cai W; Zhou C
    Cancer Med; 2018 Jan; 7(1):32-45. PubMed ID: 29168339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
    He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR
    Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.
    Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J
    Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic changes in PD-L1 expression and CD8
    Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
    Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
    Mandarano M; Bellezza G; Belladonna ML; Van den Eynde BJ; Chiari R; Vannucci J; Mondanelli G; Ludovini V; Ferri I; Bianconi F; Del Sordo R; Cagini L; Albini E; Metro G; Puma F; Sidoni A
    Virchows Arch; 2019 Feb; 474(2):159-168. PubMed ID: 30448912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
    Amemiya R; Miyoshi T; Aokage K; Suzuki J; Hoshino H; Udagawa H; Tane K; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Goto K; Ikeda N; Tsuboi M; Ishii G
    Lung Cancer; 2021 Mar; 153():56-65. PubMed ID: 33454518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma.
    Kinoshita F; Takada K; Yamada Y; Oku Y; Kosai K; Ono Y; Tanaka K; Wakasu S; Oba T; Osoegawa A; Tagawa T; Shimokawa M; Oda Y; Mori M
    Ann Surg Oncol; 2020 Jun; 27(6):2102-2109. PubMed ID: 31773516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
    Gachechiladze M; Škarda J; Skanderová D; Überall I; Kolek V; Smičkova P; Vojta P; Vbrková J; Hajdúch M; Shani I; Kolář Z; Stahel R; Weder W; Rulle U; Soltermann A; Joerger M
    Lung Cancer; 2020 Sep; 147():30-38. PubMed ID: 32653671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
    Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C
    Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.